US Prediabetes Management Market Industry Trends and Forecast to 2034: Segmented by (Approach, Setting, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
US · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$2.02 BnPlaceholder estimate
Estimate 2025$2.17 Bn43.5% of the global market
Projected 2034$4.10 Bn 88.5%Adds $1.92 Bn over 9 forecast years
CAGR 2025–20347.3%Faster than 54% of 107 Healthcare Services markets here
Key players5
US is 43.53% of the global market.
In North America, the largest is US (this report) at $2.17 Bn.
Omada Health, Abbott Laboratories, Roche Diagnostics, Merck KGaA, Teladoc Health (see all)
Active clinical trials
153 in the USSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The US Prediabetes Management Market Analysis Executive Summary
Prediabetes management covers tests, programs, medicines and digital tools that help people with raised blood sugar avoid type 2 diabetes.
Key segments of the prediabetes Management market include approach (Lifestyle Programs, Medication and Digital Coaching) and setting (Primary Care, Workplace Programs and Home).
US Prediabetes Management market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
US Prediabetes Management Market Dynamics
Market Growth Drivers
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the prediabetes Management market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.
Opportunity
Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the prediabetes Management market, especially in fast-growing emerging economies.
Market Restraints
High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the prediabetes Management market. Long-term safety data and lifestyle support are still needed for many patients.
Competitive Landscape for Prediabetes Management Market in US
The prediabetes Management market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Prediabetes Management Market in US
Prediabetes Management in the US: payment and research
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).[1] ClinicalTrials.gov lists 153 studies on Prediabetes Management that are recruiting, active or about to start in the US.[2] Diabetes (adults): 12.5% of adults in 2022, the latest WHO figure for the US.[3]
Licensing, quality standards and payment models from public and private payers shape how prediabetes Management services are delivered and paid for in US. Government health programs and insurance coverage are key to access.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Approach
4.2 By Setting
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Omada Health
7.2 Abbott Laboratories
7.3 Roche Diagnostics
7.4 Merck KGaA
7.5 Teladoc Health
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The prediabetes Management market can be segmented based on various criteria, including approach, setting and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Prediabetes Management right now, from free public sources.
How big is the Prediabetes Management market in the US?
Placeholder estimate: about $2.17 Bn in 2025, rising to about $4.10 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Prediabetes Management market in the US growing?
Placeholder estimate: about 7.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Prediabetes Management market report cover?
The report splits the market by approach (Lifestyle Programs, Medication, Digital Coaching, Screening and Testing), setting (Primary Care, Workplace Programs, Home) and end user (Hospitals, Clinics, Home Care, Corporate and Payer Clients).
Who are the key players in the Prediabetes Management market?
Key players include Omada Health, Abbott Laboratories, Roche Diagnostics, Merck KGaA and Teladoc Health.
What is driving the Prediabetes Management market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the prediabetes Management market.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How many clinical trials on Prediabetes Management are running in the US?
153 studies are recruiting, active or about to start in the US, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
What does WHO report for the US?
Diabetes (adults): 12.5% of adults in 2022, the latest WHO figure. Source: WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 15 Nov 2026.
How many people in the US are 65 or older?
18.4% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 18 Nov 2026.
How much research is published on Prediabetes Management?
PubMed lists 57 papers on Prediabetes Management added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.